查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1370967

限制性内切酶市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按类型、按应用、最终用户、地区和竞争细分

Restriction Endonuclease Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type, By Application, By End User, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 170 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2022 年全球限制性内切酶市场价值为 3.7076 亿美元，预计在整个预测期内将呈现强劲增长，复合年增长率 (CAGR) 为 6.53%，预计到 2028 年将达到 5.3468 亿美元。在称为限制性位点的特定辨识核苷酸序列处切割DNA 的酵素。这些源自细菌的酵素在研究和商业领域都有应用。限制性内切酶根据其结构和切割特征分为四种类型。这些酵素在分子生物学和遗传学研究中发挥关键作用，能够透过靶向特定位点来精确操作 DNA。它们的重要性在 DNA 克隆、基因编辑、基因工程和 DNA 分析中尤其显着。

主要市场驱动因素

增加资金

市场概况
预测期 2024-2028
2022 年市场规模 37076万美元
2028 年市场规模 5.3468亿美元
2023-2028 年复合年增长率 6.53%
成长最快的细分市场 医院
最大的市场 北美洲

生物技术和製药公司的资金和投资的注入正在显着塑造全球限制性内切酶产品 (REP) 市场。这些酵素在限制性消化、克隆和测序等应用中的广泛应用也促进了市场成长。资金的增加使研究人员能够开展综合研究项目，包括遗传分析、基因编辑和 DNA 操作，推动了对限制性内切酶的需求。此外，增加的资金支持大规模基因组研究，包括全基因组关联研究（GWAS）和全基因组定序项目，刺激了对用于资料分析和验证的限制性内切酶的需求。 CRISPR-Cas9等依赖于限制性内切酶的基因编辑技术的开发和优化受益于资金的增加，从而增加了对这些酶的需求。

增加研发项目

生物技术和分子生物学的进步导致限制性内切酶新应用的发现。这些酵素在 DNA 克隆、基因编辑和基因工程等技术中发挥关键作用。随着这些领域的发展，对促进 DNA 操作和修饰的限制性内切酶的需求不断增加。随着研究人员开发新的基因编辑技术或改进现有技术，对具有独特识别序列或增强特异性的限制性内切酶的需求预计将会成长。限制性内切酶在生物分子研究中也发挥至关重要的作用，需要精确操作遗传物质。该领域研究的扩展可以进一步推动对这些酶的需求。

老年人口增加

全球老年人口的成长预计将推动医学研究、诊断和个人化医疗领域对限制性内切酶的需求。随着人们越来越关注与年龄相关疾病的遗传基础，限制性内切酶成为 DNA 分析、基因定序和基因分型不可或缺的工具。需要根据其遗传特征进行个人化药物治疗的老年患者数量的增加预计将推动药物基因组学研究中对限制性内切酶的需求。

慢性病病例不断增加

具有遗传成分的主要慢性疾病的病例不断增加，导致基因研究、诊断和治疗干预措施的加强。限制性内切酶对于 DNA 分析和基因分型至关重要，使研究人员能够识别与这些疾病相关的遗传变异。人们越来越关注了解慢性疾病的遗传基础，预计将推动对这些酵素的需求。

主要市场挑战

生产成本高

限制性内切酶的生产涉及复杂的过程，包括发酵、纯化和品质控制。这些过程是资源密集的，需要专门的设备和专业知识。相关成本导致限制酶产品价格上涨，可能会阻碍预算有限的研究人员和实验室采用它们。

缺乏严格的品质管制

在整个生产过程中保持严格的品质控制措施对于确保限制性酵素产品的一致性和可靠性至关重要。批次之间的差异可能导致实验结果不可靠，浪费时间和资源。透明和全面的品质保证实践可以在产品一致性和性能方面向研究人员灌输信任。

主要市场趋势

不断崛起的创新技术

DNA 定序和基因表现等新颖方法的采用正在为全球限制性内切核酸酶产品市场的製造商和利害关係人带来成长机会。 DNA 定序技术，包括下一代定序，彻底改变了基因组学研究。限制性内切酶在製备用于定序的 DNA 样本、支持基因组学研究和实现个人化医疗方法方面发挥着至关重要的作用。

不断增加的政府倡议

支持研究活动的政府措施预计将推动市场成长。政府在基因组学、个人化医疗、基因编辑和生物技术等领域的资助可以导致依赖限制性内切酶的研究计画的扩展。这些措施可以塑造研究方向和技术发展，影响对限制性内切酶等基本研究工具的需求。

细分市场洞察

类型洞察

在限制性内切酶的类型中，I 型酶切由于其在具有挑战性的目标和较长序列上切割 DNA 的特异性，占据了最大的市场收入份额。

最终使用者见解

製药和生物技术公司在限制性内切酶产品市场的最终用户领域占有重要地位，预计将大幅成长。製药公司对基因疗法和限制性内切酶产品应用的投资预计将推动市场扩张。这些酵素使研究人员能够研究疾病的遗传基础、发现潜在的药物标靶、开发治疗药物并推进个人化医疗方法。

区域洞察

由于杰出参与者的存在和研究活动的进步，北美在限制性内切酶产品市场上处于领先地位。併购有助于市场成长。在生物技术和製药公司、私人和政府研究组织以及消费者对技术进步的认识不断提高的推动下，亚太地区正在经历巨大的市场成长。

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：客户之声

第 5 章：全球限制性内切核酸酶市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型（I 型、II 型、III 型和 IV 型）
    • 按应用（基因工程、DNA 作图、基因定序等）
    • 按最终用户（製药和生物技术公司、学术研究机构等）
    • 按地区
    • 按公司划分 (2022)
  • 市场地图

第 6 章：北美限制性内切核酸酶市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按应用
    • 按最终用户
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第 7 章：欧洲限制性内切核酸酶市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按应用
    • 按最终用户
    • 按国家/地区
  • 欧洲：国家分析
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙

第 8 章：亚太地区限制性内切酶市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按应用
    • 按最终用户
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第 9 章：南美洲限制性内切核酸酶市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按应用
    • 按最终用户
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲限制性内切市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按应用
    • 按最终用户
    • 按国家/地区
  • MEA：国家分析
    • 南非限制性内切酶
    • 沙乌地阿拉伯限制性内切酶
    • 阿联酋限制性内切酶

第 11 章：市场动态

第 12 章：市场趋势与发展

第 13 章：全球限制性内切核酸酶市场：SWOT 分析

第14章：竞争格局

  • 商业概览
  • 服务产品
  • 最近的发展
  • 主要人员
  • SWOT分析
    • Agilent Technologies, Inc.
    • Thermo Fisher Scientific Inc.
    • Affymetrix, Inc.
    • Illumina, Inc.
    • Enzymatics, Inc.
    • QIAGEN NV
    • New England Biolabs, Inc.
    • Sigma-Aldrich Co. LLC.
    • Roche, Ltd.
    • Takara Bio, Inc

第 15 章：策略建议

第 16 章：关于我们与免责声明

简介目录
Product Code: 4638

The Global Restriction Endonuclease Market was valued at USD 370.76 Million in 2022 and is expected to exhibit robust growth throughout the forecast period, with a Compound Annual Growth Rate (CAGR) of 6.53% and expected to reach USD 534.68 Million through 2028. Restriction endonucleases are enzymes that cleave DNA at specific recognition nucleotide sequences known as restriction sites. These enzymes, derived from bacteria, find application in both research and commercial contexts. Restriction enzymes are classified into four types based on their structure and cleavage characteristics. These enzymes play a pivotal role in molecular biology and genetic research, enabling precise manipulation of DNA by targeting specific sites. Their significance is particularly notable in DNA cloning, gene editing, genetic engineering, and DNA analysis.

Key Market Drivers

Increasing Funding

Market Overview
Forecast Period2024-2028
Market Size 2022USD 370.76 Million
Market Size 2028USD 534.68 Million
CAGR 2023-20286.53%
Fastest Growing SegmentHospitals
Largest MarketNorth America

The infusion of funding and investments from biotechnology and pharmaceutical companies is significantly shaping the global restriction endonucleases products (REP) market. The expanding utilization of these enzymes for applications such as restriction digestion, cloning, and sequencing is also fostering market growth. Enhanced funding allows researchers to undertake comprehensive research projects, including genetic analysis, gene editing, and DNA manipulation, driving the demand for restriction endonucleases. Moreover, increased funding supports large-scale genomic studies, including genome-wide association studies (GWAS) and whole-genome sequencing projects, fueling the demand for restriction endonucleases for data analysis and validation. The development and optimization of gene editing technologies like CRISPR-Cas9, which rely on restriction endonucleases, benefit from increased funding, boosting the demand for these enzymes.

Increasing Research and Development Projects

Advancements in biotechnology and molecular biology lead to the discovery of novel applications for restriction endonucleases. These enzymes play a pivotal role in techniques such as DNA cloning, gene editing, and genetic engineering. As these fields evolve, the demand for restriction endonucleases to facilitate DNA manipulation and modification is on the rise. As researchers develop new gene editing techniques or improve existing ones, the demand for restriction endonucleases with unique recognition sequences or enhanced specificity is expected to grow. Restriction endonucleases also play a vital role in studying biomolecules, requiring precise manipulation of genetic material. The expansion of research in this domain can further drive the demand for these enzymes.

Rising Geriatric Population

The growing global geriatric population is expected to drive demand for restriction endonucleases in medical research, diagnostics, and personalized medicine. With an increasing focus on understanding the genetic basis of age-related diseases, restriction endonucleases become indispensable tools for DNA analysis, gene sequencing, and genotyping. The rise in geriatric patients requiring personalized drug regimens aligned with their genetic profiles is expected to drive demand for restriction endonucleases in pharmacogenomic studies.

Increasing Instances of Chronic Diseases

The growing instances of major chronic diseases with genetic components are leading to intensified genetic research, diagnostics, and therapeutic interventions. Restriction endonucleases are vital for DNA analysis and genotyping, allowing researchers to identify genetic variations associated with these diseases. This growing focus on understanding the genetic underpinnings of chronic diseases is expected to drive demand for these enzymes.

Key Market Challenges

High Cost of Production

The production of restriction endonucleases involves complex processes, including fermentation, purification, and quality control. These processes are resource-intensive and demand specialized equipment and expertise. The associated costs contribute to higher prices for restriction enzyme products, potentially hindering their adoption by researchers and laboratories with limited budgets.

Lack of Stringent Quality Control

Maintaining stringent quality control measures throughout the production process is essential to ensure consistency and reliability of restriction enzyme products. Variability between batches can lead to unreliable experimental results, wasting time and resources. Transparent and comprehensive quality assurance practices can instill trust in researchers regarding product consistency and performance.

Key Market Trends

Rising Innovative Techniques

The adoption of novel methodologies like DNA sequencing and gene expression is driving growth opportunities for manufacturers and stakeholders in the global restriction endonucleases products market. DNA sequencing technologies, including next-generation sequencing, have revolutionized genomics research. Restriction endonucleases play a crucial role in preparing DNA samples for sequencing, supporting genomics research and enabling personalized medicine approaches.

Rising Government Initiatives

Government initiatives supporting research activities are expected to drive market growth. Government funding in areas like genomics, personalized medicine, gene editing, and biotechnology can lead to expanded research projects relying on restriction endonucleases. These initiatives can shape research directions and technological developments, influencing the demand for essential research tools like restriction endonucleases.

Segmental Insights

Type Insights

Among the types of restriction enzymes, the type I segment holds the largest market revenue share due to its specificity in cleaving DNA at challenging targets and longer sequences.

End User Insights

Pharmaceutical & Biotechnology Companies have a significant presence in the end-user segment of the Restriction Endonucleases Products market and are projected to experience substantial growth. The investment by pharmaceutical companies in gene therapies and applications of Restriction Endonucleases Products is expected to drive market expansion. These enzymes enable researchers to study the genetic basis of diseases, discover potential drug targets, develop therapeutic agents, and advance personalized medicine approaches.

Regional Insights

North America leads the Restriction Endonucleases Products Market, attributed to the presence of prominent players and advancements in research activities. Mergers and acquisitions contribute to market growth. Asia Pacific is experiencing substantial market growth, driven by biotechnology and pharmaceutical companies, private and government research organizations, and increasing consumer awareness of technological advancements.

Key Market Players

  • Agilent Technologies, Inc.
  • Thermo Fisher Scientific Inc.
  • Affymetrix, Inc.
  • Illumina, Inc.
  • Enzymatics, Inc.
  • QIAGEN N.V.
  • New England Biolabs, Inc.
  • Sigma-Aldrich Co. LLC.
  • Roche, Ltd.
  • Takara Bio, Inc.

Report Scope:

In this report, the Global Restriction Endonuclease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Restriction Endonuclease Market, By Type:

  • Type I
  • Type II
  • Type III
  • Type IV

Restriction Endonuclease Market, By Application:

  • Genetic Engineering
  • DNA Mapping
  • Gene Sequencing
  • Others

Restriction Endonuclease Market, By End User:

  • Pharmaceutical & Biotechnology Companies
  • Academic Research Institutes
  • Others

Restriction Endonuclease Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Restriction Endonuclease Market.

Available Customizations:

  • Global Restriction Endonuclease market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Restriction Endonuclease Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Type I, Type II, Type III, and Type IV)
    • 5.2.2. By Application (Genetic Engineering, DNA Mapping, Gene Sequencing, and Others)
    • 5.2.3. By End User (Pharmaceutical & Biotechnology Companies, Academic Research Institutes, and Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2022)
  • 5.3. Market Map

6. North America Restriction Endonuclease Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Restriction Endonuclease Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Restriction Endonuclease Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Restriction Endonuclease Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End User

7. Europe Restriction Endonuclease Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Restriction Endonuclease Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End User
    • 7.3.2. United Kingdom Restriction Endonuclease Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End User
    • 7.3.3. Italy Restriction Endonuclease Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End User
    • 7.3.4. France Restriction Endonuclease Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Restriction Endonuclease Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End User

8. Asia-Pacific Restriction Endonuclease Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Restriction Endonuclease Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End User
    • 8.3.2. India Restriction Endonuclease Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Restriction Endonuclease Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Restriction Endonuclease Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Restriction Endonuclease Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End User

9. South America Restriction Endonuclease Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Restriction Endonuclease Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Restriction Endonuclease Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Restriction Endonuclease Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End User

10. Middle East and Africa Restriction Endonuclease Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Restriction Endonuclease Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Restriction Endonuclease Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Restriction Endonuclease Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End User

11. Market Dynamics

12. Market Trends & Developments

13. Global Restriction Endonuclease Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Business Overview
  • 14.2. Services Offerings
  • 14.3. Recent Developments
  • 14.4. Key Personnel
  • 14.5. SWOT Analysis
    • 14.5.1. Agilent Technologies, Inc.
    • 14.5.2. Thermo Fisher Scientific Inc.
    • 14.5.3. Affymetrix, Inc.
    • 14.5.4. Illumina, Inc.
    • 14.5.5. Enzymatics, Inc.
    • 14.5.6. QIAGEN N.V.
    • 14.5.7. New England Biolabs, Inc.
    • 14.5.8. Sigma-Aldrich Co. LLC.
    • 14.5.9. Roche, Ltd.
    • 14.5.10. Takara Bio, Inc

15. Strategic Recommendations

16. About Us & Disclaimer